CB Scientific, Inc. Appoints Paul Danner as Chairman
CB Scientific has appointed Paul K. Danner as Chairman of its Board of Directors, effective immediately. Danner brings over 25 years of experience with Nasdaq-listed companies. His leadership aims to enhance the company’s executive team amid plans for a timely uplist to the OTCQB Venture Market, pending a completed audit by MaloneBailey LLP. Danner expressed excitement about the company’s growth potential, focusing on expanding both domestically and internationally. CB Scientific provides innovative cardiac monitoring solutions, emphasizing their commitment to transparency with future announcements.
- Appointment of Paul K. Danner as Chairman could strengthen leadership.
- Danner's extensive Nasdaq experience may bring valuable insights.
- Plans to uplist to OTCQB could enhance trading transparency and investor access.
- None.
The addition marks the first in a series of executive leadership enhancements intended to position CBSC for accelerated success
ESCONDIDO, CA / ACCESSWIRE / October 28, 2021 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") is a provider of remote ECG cardiac monitoring products and services; simple wearable solutions for detecting potentially life-threatening heart arrhythmias in patients with heart-related issues, both domestically and internationally.
The Company has announced today that Paul K. Danner has been appointed as Chairman of its Board of Directors effective immediately. Mr. Danner has previously served with three Nasdaq-listed companies as the senior corporate executive and has acquired extensive Board of Director expertise through multiple appointments totaling more than twenty-five years with Nasdaq and OTCQB-listed companies.
"We are extremely pleased that Paul accepted this critical leadership position with CB Scientific," said Charles Martin, Chief Executive Officer of CB Scientific, Inc. "He brings a broad base of business experience and a wealth of corporate governance proficiency, which we believe will materially strengthen our executive team as we seek to propel the Company forward," he added.
The Company is also currently engaged with MaloneBailey LLP to conclude its audit that will be included in an annual report to be filed with OTC Markets. Completing this significant milestone is expected to qualify CBSC for a timely uplist to the OTCQB Venture Market, which offers investors transparent trading in entrepreneurial and development stage U.S. and international companies.
"I am genuinely excited to become affiliated with an enterprise that offers such tremendous growth potential as CB Scientific," said Paul Danner, newly appointed Chairman of CBSC. "The domestic and offshore market opportunities for us to expand this business are extraordinary, and I plan to add as much impactful value to that effort as quickly and as thoroughly as possible."
As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.
About CB Scientific, Inc.
CB Scientific (https://cbscientificinc.com/), through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.
Company Contact Information:
Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse - dorchco.bh@gmail.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: CB Scientific, Inc.
View source version on accesswire.com:
https://www.accesswire.com/670058/CB-Scientific-IncAppoints-Paul-Danner-as-Chairman
FAQ
Who is Paul K. Danner and what is his role at CB Scientific?
What does CB Scientific do?
What are the implications of the appointment of Paul Danner for CB Scientific?
What is the significance of the planned uplist to OTCQB for CB Scientific?
